MiniMed VP granted 24,244 RSUs in equity award

MiniMed Group, Inc. executive Gyurci John, VP and Chief Accounting Officer, reported an equity compensation grant rather than a market purchase or sale.

Rhea-AI Filing Summary

MiniMed Group, Inc. executive Gyurci John, VP and Chief Accounting Officer, reported an equity compensation grant rather than a market purchase or sale. He received 24,244 shares of Common Stock as a grant of restricted stock units under the 2026 Long Term Incentive Plan, with these RSUs vesting in approximately equal one-third increments on the first, second and third anniversaries of the grant date. Following this award, his directly held position is reported as 39,941 shares of common stock, which includes shares issuable upon vesting of one or more RSUs and 375 shares acquired through MiniMed’s 2026 Employee Stock Purchase Plan.

Insider Trade Summary

Grant/Award: 24,244 shares

Grant/Award 1 txn

Insider Gyurci John

Role VP, Chief Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	24,244	$0.00	$0.00

Holdings After Transaction: Common Stock — 39,941 shares (Direct)

Footnotes (3)

1. F1. Represents the grant of restricted stock units ("RSUs") pursuant to the 2026 MiniMed Group, Inc. Long Term Incentive Plan that vest in approximately equal one-third increments on the first, second and third anniversaries of the grant date.
2. F2. Includes shares of common stock to be issued in connection with the vesting of one or more RSUs.
3. F3. Includes 375 shares acquired under MMED's 2026 Employee Stock Purchase Plan on June 30, 2026.

Key Figures

RSU grant size: 24,244 shares Grant price per share: $0.0000 per share Shares held after transaction: 39,941 shares +2 more

5 metrics

RSU grant size 24,244 shares Restricted stock units granted on July 1, 2026

Grant price per share $0.0000 per share Reported transaction price for RSU grant

Shares held after transaction 39,941 shares Total direct common stock holdings after grant

ESPP shares included 375 shares Shares acquired under 2026 Employee Stock Purchase Plan

RSU vesting schedule Three equal one-third increments First, second and third anniversaries of grant date

Key Terms

restricted stock units ("RSUs"), Long Term Incentive Plan, Employee Stock Purchase Plan

3 terms

restricted stock units ("RSUs") financial

"Represents the grant of restricted stock units ("RSUs") pursuant to the 2026 MiniMed Group, Inc. Long Term Incentive Plan"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Long Term Incentive Plan financial

"pursuant to the 2026 MiniMed Group, Inc. Long Term Incentive Plan that vest in approximately equal one-third increments"

A long term incentive plan is a company program that awards executives and key employees bonuses—often in stock, options, or cash—only if the business meets multi-year performance goals. It links management pay to company results—like tying a coach’s bonus to a team’s multi-season record—so investors monitor it for how leaders are motivated, potential share dilution, and signals about the company’s long-term priorities.

Employee Stock Purchase Plan financial

"Includes 375 shares acquired under MMED's 2026 Employee Stock Purchase Plan on June 30, 2026."

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

FAQ

What insider transaction did MiniMed (MMED) report for Gyurci John?

MiniMed reported that VP and Chief Accounting Officer Gyurci John received 24,244 shares of Common Stock via a restricted stock unit grant. This is a compensation award under the 2026 Long Term Incentive Plan, not an open-market stock purchase or sale.

How many MiniMed (MMED) shares does Gyurci John hold after this Form 4?

After the reported grant, Gyurci John is shown holding 39,941 shares of MiniMed common stock directly. This figure includes shares that will be issued upon vesting of RSUs and 375 shares acquired through the 2026 Employee Stock Purchase Plan.

How do the MiniMed (MMED) RSUs granted to Gyurci John vest?

The 24,244 restricted stock units granted to Gyurci John vest in three stages. They vest in approximately equal one-third increments on the first, second and third anniversaries of the grant date, aligning payout with multi-year service and performance horizons.

Was cash paid for the MiniMed (MMED) shares reported in this Form 4?

No cash purchase is indicated for this transaction. The 24,244 MiniMed shares were granted at a reported price per share of $0.0000, reflecting a stock-based compensation award rather than an open-market buy by the executive.

What MiniMed (MMED) equity plans are referenced in Gyurci John’s Form 4?

The filing references MiniMed’s 2026 Long Term Incentive Plan and its 2026 Employee Stock Purchase Plan. The RSU grant comes from the long-term incentive plan, and 375 additional shares are noted as acquired under the employee stock purchase plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/06/2026 - 05:44 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gyurci John

(Last) (First) (Middle)

C/O MINIMED GROUP, INC.

18000 DEVONSHIRE STREET

(Street)

NORTHRIDGE CALIFORNIA 91325

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MiniMed Group, Inc. [ MMED ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Chief Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		A		24,244(1)	A	$0	39,941(2)(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the grant of restricted stock units ("RSUs") pursuant to the 2026 MiniMed Group, Inc. Long Term Incentive Plan that vest in approximately equal one-third increments on the first, second and third anniversaries of the grant date.

2. Includes shares of common stock to be issued in connection with the vesting of one or more RSUs.

3. Includes 375 shares acquired under MMED's 2026 Employee Stock Purchase Plan on June 30, 2026.

Remarks:

	/s/ Bryan F. Kelly, attorney-in-fact	07/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)